Sarah Gheuens's Insider Trades & SAST Disclosures

Sarah Gheuens's most recent trade in Agios Pharmaceuticals Inc was a trade of 11,914 Stock options (right to buy) done . Disclosure was reported to the exchange on July 9, 2025.

Stock Client Name Client Category Action Reported to Exchange Quantity Post Transaction Holding Traded % Avg. Price Value Security Type
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 09 Jul 2025 11,914 32,086 - - Stock options (right to buy)
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.01 per share. 09 Jul 2025 11,914 73,185 (0%) 0% 25.0 297,969 Common stock
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Sale of securities on an exchange or to another person at price $ 37.93 per share. 09 Jul 2025 11,067 62,118 (0%) 0% 37.9 419,771 Common stock
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Sale of securities on an exchange or to another person at price $ 38.76 per share. 09 Jul 2025 847 61,271 (0%) 0% 38.8 32,830 Common stock
Viridian Therapeutics Inc
Sarah Gheuens Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Jul 2025 21,000 21,000 - - Stock Option (Right to Buy)
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 01 Jul 2025 8,374 65,362 (0%) 0% 0 Common stock
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 01 Jul 2025 8,374 8,375 - - Restricted stock units
Agios Pharmaceuticals Inc
Gheuens Sarah Chief Medical Officer Sale of securities on an exchange or to another person at price $ 34.17 per share. 01 Jul 2025 4,091 61,271 (0%) 0% 34.2 139,789 Common stock
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 24 Jun 2025 6,000 59,897 (0%) 0% 0 Common stock
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 24 Jun 2025 6,000 6,000 - - Performance share units
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Sale of securities on an exchange or to another person at price $ 33.54 per share. 24 Jun 2025 2,909 56,988 (0%) 0% 33.5 97,568 Common stock
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Mar 2025 43,500 43,500 - - Stock options (right to buy)
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Mar 2025 12,000 12,000 - - Restricted stock units
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 01 Mar 2025 5,667 55,578 (0%) 0% 0 Common stock
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 01 Mar 2025 5,667 11,333 - - Restricted stock units
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 01 Mar 2025 4,000 4,000 - - Restricted stock units
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 01 Mar 2025 4,000 51,098 (0%) 0% 0 Common stock
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 01 Mar 2025 3,833 48,235 (0%) 0% 0 Common stock
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 01 Mar 2025 3,833 0 - - Restricted stock units
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Sale of securities on an exchange or to another person at price $ 35.54 per share. 01 Mar 2025 1,681 53,897 (0%) 0% 35.5 59,743 Common stock
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Sale of securities on an exchange or to another person at price $ 35.54 per share. 01 Mar 2025 1,187 49,911 (0%) 0% 35.5 42,186 Common stock
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Sale of securities on an exchange or to another person at price $ 35.54 per share. 01 Mar 2025 1,137 47,098 (0%) 0% 35.5 40,409 Common stock
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 01 Jul 2024 8,375 47,441 (0%) 0% 0 Common stock
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 01 Jul 2024 8,375 16,749 - - Restricted stock units
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Sale of securities on an exchange or to another person at price $ 43.85 per share. 01 Jul 2024 3,705 43,736 (0%) 0% 43.8 162,464 Common stock
Viridian Therapeutics Inc
Sarah Gheuens Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 26 Jun 2024 21,000 21,000 - - Stock Option (Right to Buy)
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Mar 2024 60,000 60,000 - - Stock options (right to buy)
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Mar 2024 17,000 17,000 - - Restricted stock units
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 01 Mar 2024 4,000 40,415 (0%) 0% 0 Common stock
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 01 Mar 2024 4,000 8,000 - - Restricted stock units
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 01 Mar 2024 3,834 37,708 (0%) 0% 0 Common stock
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 01 Mar 2024 3,834 3,833 - - Restricted stock units
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Sale of securities on an exchange or to another person at price $ 32.57 per share. 01 Mar 2024 1,349 39,066 (0%) 0% 32.6 43,937 Common stock
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Sale of securities on an exchange or to another person at price $ 32.57 per share. 01 Mar 2024 1,293 36,415 (0%) 0% 32.6 42,113 Common stock
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 12 Feb 2024 2,162 0 - - Restricted stock units
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 12 Feb 2024 2,162 34,073 (0%) 0% 0 Common stock
Agios Pharmaceuticals Inc
Gheuens Sarah Chief Medical Officer Sale of securities on an exchange or to another person at price $ 25.14 per share. 12 Feb 2024 642 33,431 (0%) 0% 25.1 16,140 Common stock
Agios Pharmaceuticals Inc
Gheuens Sarah Chief Medical Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 20 Jan 2024 5,750 0 - - Performance share units
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 20 Jan 2024 5,750 33,619 (0%) 0% 0 Common stock
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Sale of securities on an exchange or to another person at price $ 21.64 per share. 20 Jan 2024 1,708 31,911 (0%) 0% 21.6 36,961 Common stock
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 05 Jan 2024 5,000 29,658 (0%) 0% 0 Common stock
Agios Pharmaceuticals Inc
Gheuens Sarah Chief Medical Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 05 Jan 2024 5,000 0 - - Performance share units
Agios Pharmaceuticals Inc
Gheuens Sarah Chief Medical Officer Sale of securities on an exchange or to another person at price $ 22.99 per share. 05 Jan 2024 1,789 27,869 (0%) 0% 23.0 41,129 Common stock
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Jul 2023 25,124 25,124 - - Restricted stock units
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 28 Jun 2023 5,750 5,750 - - Performance share units
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 28 Jun 2023 5,750 25,866 (0%) 0% 0 Common stock
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Sale of securities on an exchange or to another person at price $ 28.36 per share. 28 Jun 2023 1,707 24,159 (0%) 0% 28.4 48,411 Common stock
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Mar 2023 44,000 44,000 - - Stock options (right to buy)
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Mar 2023 12,000 12,000 - - Restricted stock units
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 01 Mar 2023 3,833 21,250 (0%) 0% 0 Common stock
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 01 Mar 2023 3,833 7,667 - - Restricted stock units
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.02 per share. 01 Mar 2023 1,134 20,116 (0%) 0% 25.0 28,373 Common stock
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 10 Feb 2023 2,162 2,162 - - Restricted stock units
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 10 Feb 2023 2,162 17,767 (0%) 0% 0 Common stock
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.44 per share. 10 Feb 2023 758 17,009 (0%) 0% 28.4 21,558 Common stock
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 23 Dec 2022 9,375 0 - - Restricted stock units
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 23 Dec 2022 9,375 18,388 (0%) 0% 0 Common stock
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.48 per share. 23 Dec 2022 2,783 15,605 (0%) 0% 28.5 79,260 Common stock
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 02 Dec 2022 833 0 - - Restricted stock units
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 02 Dec 2022 833 9,261 (0%) 0% 0 Common stock
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.83 per share. 02 Dec 2022 248 9,013 (0%) 0% 28.8 7,150 Common stock
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Mar 2022 41,000 41,000 - - Stock options (right to buy)
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Mar 2022 11,500 11,500 - - Restricted stock units
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 18 Feb 2022 3,271 3,272 - - Performance share units
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 18 Feb 2022 3,271 8,723 (0%) 0% 0 Common stock
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.08 per share. 18 Feb 2022 955 7,768 (0%) 0% 29.1 27,771 Common stock
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 10 Feb 2022 2,162 4,324 - - Restricted stock units
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 10 Feb 2022 2,162 6,210 (0%) 0% 0 Common stock
Agios Pharmaceuticals Inc
Sarah Gheuens Chief Medical Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.42 per share. 10 Feb 2022 758 5,452 (0%) 0% 31.4 23,820 Common stock
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc  
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges
View All The Insider Trades